Tag Archives: American Academy of Neurology

April, 2018

25 April
Ionis’ Investigational Huntington’s Disease Drug Demonstrates Lowering of the Disease-Causing Protein and Improvement in Clinical Measures in Phase 1/2 Study

CARLSBAD, Calif., April 24, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today presented top-line data from the Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington’s disease (HD) at the 70th American Academy of Neurology (AAN) meeting in Los Angeles, California. …
Share
23 April
Ocrevus Significantly Reduces Disease Activity and Disability Progression in Relapsing Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple …
Share

26 April
New Data from Genzyme’s Phase 3 Study Suggest Positive Effects of Aubagio on Cortical Gray Matter Atrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® (teriflunomide) on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology (AAN) …
Share
24 April
Tecfidera and Tysabri Data Demonstrate Improved Outcomes with Early MS Treatment

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may improve outcomes for people living with relapsing MS. These data were presented at the 69th annual meeting …
Share

12 April
Over-the-Counter Drug May Reverse Chronic Vision Damage Caused by Multiple Sclerosis

VANCOUVER, British Columbia, April 12, 2016 /PRNewswire-USNewswire/ — A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American …
Share